TB deaths remain a serious challenge when patients arrive already severely ill, and many lose their lives soon after diagnosis. Tamil Nadu now shows clear progress by cutting TB deaths by at least 38 percent through its statewide care initiative.
Cancer drug price cuts are expected to save patients Rs 3,540 crore annually, improving affordability through revised medicine prices.
Morepen expands its US pharma business beyond API manufacturing with its first prescription generic launch, strengthening its presence in the US market.
Liquid biopsy, a blood-based testing approach, could help doctors make more precise treatment decisions by identifying cancer-related information in the bloodstream.
Two major heart trials from Novartis and Novo Nordisk have delivered a sobering message for cardiovascular drug development.
Moderna raises its 2026 revenue growth outlook to 15%-25% as strong COVID vaccine demand from overseas markets and partnership payments lift results.
Pharma companies delivered contrasting earnings signals this week, with some reporting sharp profit declines while others recorded strong growth.
India’s air pollution problem needs more than seasonal restrictions and emergency measures. Clear PM2.5 targets could help the country measure progress towards cleaner air and better public health.
The latest FDA findings have renewed concerns about India's drug quality, after inspectors identified serious data integrity violations, discarded manufacturing records, and unacceptable hygiene conditions at pharmaceutical facilities.
Glenmark Pharma reported a sharp 56.78% year-on-year decline in consolidated net profit to Rs 263.83 crore in Q2 FY27, reflecting significant pressure on its quarterly earnings.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
